SCHEMBL6434187

SCHEMBL6434187

COC(=O)c1ccc(OC)c(NS(=O)(=O)c2ccc3c(Cl)cnc(Cl)c3c2)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.60
ALDH1A1 P00352 5/20 0.55
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
ACLY P53396 7/20 0.49
TSHR P16473 2/20 0.48
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TP53 P04637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PKM P14618 1/20 0.46
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PLG P00747 1/20 0.43
PLAU P00749 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6434188 0.86 CYP2C9 (0.53) CYP2C9ALDH1A1KMT2AMEN1ACLY
Hydrochloric Acid SCHEMBL6434449 0.78 ACLY (0.48) CYP2C9ALDH1A1KMT2AMEN1ACLY
SCHEMBL6434632 0.73 PLAU (0.55) CYP2C9ALDH1A1KMT2AMEN1TSHR
SCHEMBL6436568 0.73 PLG (0.56) ALDH1A1KMT2AMEN1SMN1; SMN2TP53
SCHEMBL6432817 0.72 PLG (0.74) CYP2C9ALDH1A1KMT2AMEN1ACLY
SCHEMBL23014438 0.72 ALDH1A1 (0.65) CYP2C9ALDH1A1KMT2AMEN1TSHR
SCHEMBL7369764 0.72 CYP2C9 (0.52) CYP2C9ALDH1A1KMT2AMEN1ACLY
SCHEMBL6434181 0.72 CYP2C9 (0.52) CYP2C9ALDH1A1KMT2AMEN1ACLY
SCHEMBL6437740 0.71 PLAU (0.61) ALDH1A1PLGPLAU
SCHEMBL6440735 0.71 PLAU (0.59) ALDH1A1PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CYP2C9 4559/4885ALDH1A1 2641/4885KMT2A 4810/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CYP2C9 4559/4885ALDH1A1 2641/4885KMT2A 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.